Can platelet activation markers predict preeclampsia and/or its severity?

Area of Science:

• Obstetrics and Gynecology
• Hematology
• Perinatal Medicine

Background:

• Preeclampsia is a serious pregnancy complication affecting 3-5% of pregnancies.
• It poses significant risks of morbidity and mortality to both mother and fetus.
• Accurate prediction and diagnosis are crucial for effective management.

Purpose of the Study:

• To assess the utility of platelet activation markers in predicting preeclampsia.
• To evaluate the role of these markers in determining preeclampsia severity.
• To explore potential improvements in preeclampsia management strategies.

Main Methods:

• Included 99 preeclampsia patients and 60 healthy pregnant controls.
• Evaluated platelet activation markers: mean platelet volume (MPV), platelet distribution width (PDW), platelet count, and plateletcrit.
• Assessed clinical parameters alongside platelet markers.

Main Results:

• Platelet activation markers, particularly PDW and MPV, demonstrated value in diagnosing and following preeclampsia.
• These markers were found insufficient for predicting the severity of preeclampsia.
• Further investigation is warranted for their predictive role in disease severity.

Conclusions:

• Platelet activation markers may assist in predicting, diagnosing, and managing preeclampsia.
• Additional research is necessary to establish their role in predicting preeclampsia severity.
• Findings could inform better prevention and management strategies, improving maternal and fetal outcomes.